LIMN Liminatus Pharma Net earnings per share growth this year

LIMN (Liminatus Pharma) - company brandmark

Anticipation of the start of gastric tumor therapy trials defines the market backdrop for Liminatus Pharma (LIMN), while operating losses are already priced in. The year-over-year change in EPS illustrates the current trend, with the latest value recorded as 0.00. Investment protection is provided by patents in narrow niches, while the demand for oncology treatment renders the business insensitive to economic cycles.

Liminatus Pharma LLC (LIMN): Net earnings per share growth this year from 05/02/2025 to 11/17/2026

Analytical breakdowns and data insights for company Liminatus (LIMN)

- current quotes and average value forecast:
Summary company analysis:LIMN (Liminatus Pharma)
Brand item of Liminatus Pharma Corp

This indicator measures the annual growth rate of net earnings per share, reflecting the efficiency of business scaling. By analyzing annual EPS growth, an investor assesses the company's ability to increase the return on capital. For Liminatus Pharma (LIMN), this parameter confirms the monetization of its unique GCC antigen therapy. Inelastic demand for tumor treatment provides absolute pricing power. The stable dynamics of this metric guarantee the business's resilience to inflationary shocks.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year immunocore.com|Net earnings per share growth this year januxrx.com (JANX)|Earnings per share growth in current year Arcus Biosciences Inc (RCUS)|Net earnings per share growth this year Zymeworks Corp ZYME|Tango Therapeutics Inc - Net earnings per share growth this year|Earnings growth in current year Iovance Corp IOVA|IMTX - Earnings per share growth in current year|XNCR (xencor.com) - Earnings per share growth this year|Compass Therapeutics Corp (CMPX) - Earnings per share growth in current year|Earnings per share growth rate in current year Replimune Corp (REPL)|Net earnings per share growth this year LYEL|IPHA - Net earnings per share change in current year|Net earnings per share growth this year PYXS (Pyxis Oncology, Inc.)|Net earnings per one share growth for the current year CGEN|Earnings growth in current year IOBT (IO Biotech)|Earnings per share increase in current year STRO|minktherapeutics.com - Earnings growth in current year|Earnings per share growth rate in current year Werewolf Therapeutics, Inc.|Immix (IMMX) - Earnings per share growth in current year|ALX Oncology Holdings - Earnings per share increase in current year|Earnings per share growth in current year Cue Biopharma|Earnings growth in current year pdsbiotech.com|Earnings per share growth in current year sonnetbio.com (SONN)|MAIA: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|nextcure.com (NXTC) - Earnings per share growth rate in current year|LPTX - Earnings per share growth in current year|Expected net earnings per share growth this year Intensity Therapeutics, Inc. INTS|SNSE: Earnings growth in current year|Synthetic Biologics - Earnings per share increase in current year|GRTS (Gritstone bio) - Earnings growth in current year|KA (Kineta, Inc.) - Net earnings per one share growth for the current year|Earnings growth in current year NEXI|Turnstone Biologics Corp - Earnings per share growth this year|Earnings growth in current year VCNX (Vaccinex Inc)|Harpoon Therapeutics Corp (HARP) - Earnings per share growth rate in current year